title: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
abstract: BACKGROUND
  Although it is widely believed that the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes a meta-analysis of original data from a complete set of studies comparing the norepinephrine/dopamine reuptake inhibitor (NDRI) bupropion with selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, or paroxetine).
  
  
  METHODS
  Individual patient data were pooled from a complete set of 7 randomized, double-blind studies comparing bupropion (N = 732) with SSRIs (fluoxetine, N = 339; sertraline, N = 343; paroxetine, N = 49) in outpatients with major depressive disorder (DSM-III-R or DSM-IV); 4 studies included placebo (N = 512). Response and remission rates were compared at week 8 or endpoint in both the intent-to-treat sample, using the last-observation-carried-forward (LOCF) method to account for attrition, and the observed cases. Tolerability data, including incidence of sexual side effects, were also compared.
  
  
  RESULTS
  The LOCF response and remission rates for the bupropion (62% and 47%) and SSRI (63% and 47%) groups were similar; both active therapies were superior to placebo (51% and 36%; all comparisons, p < .001). The same pattern of results was demonstrated on the observed cases analyses. Although bupropion and SSRIs were generally well tolerated, SSRI therapy resulted in significantly higher rates of sexual side effects as compared to both bupropion and placebo. SSRIs were also associated with more somnolence and diarrhea, and bupropion was associated with more dry mouth.
  
  
  CONCLUSIONS
  Bupropion and the SSRIs were equivalently effective and, overall, both treatments were well tolerated. The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
authors.affiliation: Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2593, USA. thaseme@upmc.edu
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
authors.forename: Barbara R
authors.initials: BR
authors.lastname: Haight
authors.forename: Nathalie
authors.initials: N
authors.lastname: Richard
authors.forename: Carol B
authors.initials: CB
authors.lastname: Rockett
authors.forename: Melinda
authors.initials: M
authors.lastname: Mitton
authors.forename: Jack G
authors.initials: JG
authors.lastname: Modell
authors.forename: Susan
authors.initials: S
authors.lastname: VanMeter
authors.forename: April E
authors.initials: AE
authors.lastname: Harriett
authors.forename: Younghua
authors.initials: Y
authors.lastname: Wang
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D017367:Selective Serotonin Reuptake Inhibitors